|
1
|
Travis WD, Travis LB and Devesa SS: Lung
cancer. Cancer. 75(Suppl): 191–202. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Subramanian J and Govindan R: Lung cancer
in never smokers: A review. J Clin Oncol. 25:561–570. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kenfield SA, Wei EK, Stampfer MJ, Rosner
BA and Colditz GA: Comparison of aspects of smoking among the four
histological types of lung cancer. Tob Control. 17:198–204. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gupta GP and Massagué J: Cancer
metastasis: Building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Finigan JH and Kern JA: Lung cancer
screening: Past, present and future. Clin Chest Med. 34:365–371.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Leng S, Bernauer AM, Zhai R, Tellez CS, Su
L, Burki EA, Picchi MA, Stidley CA, Crowell RE, Christiani DC, et
al: Discovery of common SNPs in the miR-205/200 family-regulated
epithelial to mesenchymal transition pathway and their association
with risk for non-small cell lung cancer. Int J Mol Epidemiol
Genet. 2:145–155. 2011.PubMed/NCBI
|
|
7
|
Pirozzi G, Tirino V, Camerlingo R, Franco
R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N and Rocco
G: Epithelial to mesenchymal transition by TGFβ-1 induction
increases stemness characteristics in primary non small cell lung
cancer cell line. PLoS One. 6:e215482011. View Article : Google Scholar
|
|
8
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
The importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maitah MY, Ali S, Ahmad A, Gadgeel S and
Sarkar FH: Up-regulation of sonic hedgehog contributes to
TGF-β1-induced epithelial to mesenchymal transition in NSCLC cells.
PLoS One. 6:e160682011. View Article : Google Scholar
|
|
10
|
Onder TT, Gupta PB, Mani SA, Yang J,
Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis
via multiple downstream transcriptional pathways. Cancer Res.
68:3645–3654. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Argast GM, Krueger JS, Thomson S,
Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ,
Young GD, et al: Inducible expression of TGFβ, snail and Zeb1
recapitulates EMT in vitro and in vivo in a NSCLC model. Clin Exp
Metastasis. 28:593–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar
|
|
13
|
Liu Y, Zhang N, Wang Y, Xu M, Liu N, Pang
X, Cao J, Ma N, Pang H, Liu L, et al: Zinc finger E-box binding
homeobox 1 promotes invasion and bone metastasis of small cell lung
cancer in vitro and in vivo. Cancer Sci. 103:1420–1428. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghahhari NM and Babashah S: Interplay
between microRNAs and WNT/β-catenin signalling pathway regulates
epithelial-mesenchymal transition in cancer. Eur J Cancer.
51:1638–1649. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi YS, Shim YM, Kim SH, Son DS, Lee HS,
Kim GY, Han J and Kim J: Prognostic significance of E-cadherin and
beta-catenin in resected stage I non-small cell lung cancer. Eur J
Cardiothorac Surg. 24:441–449. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Woenckhaus M, Merk J, Stoehr R, Schaeper
F, Gaumann A, Wiebe K, Hartmann A, Hofstaedter F and Dietmaier W:
Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small
cell lung cancer. Hum Pathol. 39:126–136. 2008. View Article : Google Scholar
|
|
18
|
Nakashima T, Liu D, Nakano J, Ishikawa S,
Yokomise H, Ueno M, Kadota K and Huang CL: Wnt1 overexpression
associated with tumor proliferation and a poor prognosis in
non-small cell lung cancer patients. Oncol Rep. 19:203–209.
2008.
|
|
19
|
Nguyen DX, Chiang AC, Zhang XH, Kim JY,
Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF signaling
through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis.
Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang R, Wang ZX, Yang JS, Pan X, De W and
Chen LB: MicroRNA-451 functions as a tumor suppressor in human
non-small cell lung cancer by targeting ras-related protein 14
(RAB14). Oncogene. 30:2644–2658. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garofalo M, Quintavalle C, Di Leva G,
Zanca C, Romano G, Taccioli C, Liu CG, Croce CM and Condorelli G:
MicroRNA signatures of TRAIL resistance in human non-small cell
lung cancer. Oncogene. 27:3845–3855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Puisségur MP, Mazure NM, Bertero T,
Pradelli L, Grosso S, Robbe-Sermesant K, Maurin T, Lebrigand K,
Cardinaud B, Hofman V, et al: miR-210 is overexpressed in late
stages of lung cancer and mediates mitochondrial alterations
associated with modulation of HIF-1 activity. Cell Death Differ.
18:465–478. 2011. View Article : Google Scholar :
|
|
23
|
Bartel DP and Chen CZ: Micromanagers of
gene expression: The potentially widespread influence of metazoan
microRNAs. Nat Rev Genet. 5:396–400. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kloosterman WP and Plasterk RH: The
diverse functions of microRNAs in animal development and disease.
Dev Cell. 11:441–450. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gabriely G, Wurdinger T, Kesari S, Esau
CC, Burchard J, Linsley PS and Krichevsky AM: MicroRNA 21 promotes
glioma invasion by targeting matrix metalloproteinase regulators.
Mol Cell Biol. 28:5369–5380. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer.
94:776–780. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang L, Li Q, Wang Q, Jiang Z and Zhang L:
Silencing of miRNA-218 promotes migration and invasion of breast
cancer via Slit2-Robo1 pathway. Biomed Pharmacother. 66:535–540.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cheng T, Hu C, Yang H, Cao L and An J:
Transforming growth factor-β-induced miR-143 expression in
regulation of non-small cell lung cancer cell viability and
invasion capacity in vitro and in vivo. Int J Oncol. 45:1977–1988.
2014.PubMed/NCBI
|
|
30
|
Luo Z, Dai Y, Zhang L, Jiang C, Li Z, Yang
J, McCarthy JB, She X, Zhang W, Ma J, et al: miR-18a promotes
malignant progression by impairing microRNA biogenesis in
nasopharyngeal carcinoma. Carcinogenesis. 34:415–425. 2013.
View Article : Google Scholar
|
|
31
|
Cong N, Du P, Zhang A, Shen F, Su J, Pu P,
Wang T, Zjang J, Kang C and Zhang Q: Downregulated microRNA-200a
promotes EMT and tumor growth through the wnt/β-catenin pathway by
targeting the E-cadherin repressors ZEB1/ZEB2 in gastric
adenocarcinoma. Oncol Rep. 29:1579–1587. 2013.PubMed/NCBI
|
|
32
|
Licchesi JD, Westra WH, Hooker CM, Machida
EO, Baylin SB and Herman JG: Epigenetic alteration of Wnt pathway
antagonists in progressive glandular neoplasia of the lung.
Carcinogenesis. 29:895–904. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gao W, Xu J, Liu L, Shen H, Zeng H and Shu
Y: A systematic-analysis of predicted miR-21 targets identifies a
signature for lung cancer. Biomed Pharmacother. 66:21–28. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang T, Chen Z and Fang L: Curcumin
inhibits LPS-induced EMT through downregulation of NF-κB-Snail
signaling in breast cancer cells. Oncol Rep. 29:117–124. 2013.
|
|
37
|
Risé P, Ghezzi S, Carissimi R, Mastromauro
F, Petroni A and Galli C: Delta5 desaturase mRNA levels are
increased by simvastatin via SREBP-1 at early stages, not via
PPARalpha, in THP-1 cells. Eur J Pharmacol. 571:97–105. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cirera-Salinas D, Pauta M, Allen RM,
Salerno AG, Ramírez CM, Chamorro-Jorganes A, Wanschel AC, Lasuncion
MA, Morales-Ruiz M, Suarez Y, et al: Mir-33 regulates cell
proliferation and cell cycle progression. Cell Cycle. 11:922–933.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Takwi AA, Li Y, Becker Buscaglia LE, Zhang
J, Choudhury S, Park AK, Liu M, Young KH, Park WY, Martin RC, et
al: A statin-regulated microRNA represses human c-Myc expression
and function. EMBO Mol Med. 4:896–909. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Williams TM, Moolten D, Burlein J, Romano
J, Bhaerman R, Godillot A, Mellon M, Rauscher FJ III and Kant JA:
Identification of a zinc finger protein that inhibits IL-2 gene
expression. Science. 254:1791–1794. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Noble S and Goa KL: Aldesleukin
(recombinant interleukin-2). BioDrugs. 7:394–422. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bhatia S, Tykodi SS and Thompson JA:
Treatment of metastatic melanoma: An overview. Oncology (Williston
Park). 23:488–496. 2009.
|
|
43
|
Shaker MA and Younes HM: Interleukin-2:
Evaluation of routes of administration and current delivery systems
in cancer therapy. J Pharm Sci. 98:2268–2298. 2009. View Article : Google Scholar
|
|
44
|
Liu W, Huang YJ, Liu C, Yang YY, Liu H,
Cui JG, Cheng Y, Gao F, Cai JM and Li BL: Inhibition of TBK1
attenuates radiation-induced epithelial-mesenchymal transition of
A549 human lung cancer cells via activation of GSK-3β and
repression of ZEB1. Lab Invest. 94:362–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Spaderna S, Schmalhofer O, Hlubek F, Berx
G, Eger A, Merkel S, Jung A, Kirchner T and Brabletz T: A
transient, EMT-linked loss of basement membranes indicates
metastasis and poor survival in colorectal cancer.
Gastroenterology. 131:830–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Dohadwala M, Yang SC, Luo J, Sharma S,
Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, et
al: Cyclo-oxygenase-2-dependent regulation of E-cadherin:
Prostaglandin E(2) induces transcriptional repressors ZEB1 and
snail in non-small cell lung cancer. Cancer Res. 66:5338–5345.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sayan AE, Griffiths TR, Pal R, Browne GJ,
Ruddick A, Yagci T, Edwards R, Mayer NJ, Qazi H, Goyal S, et al:
SIP1 protein protects cells from DNA damage-induced apoptosis and
has independent prognostic value in bladder cancer. Proc Natl Acad
Sci USA. 106:14884–14889. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang
P, He X, Wang Q, Huang Y, Jen KY, et al: CUL4A induces
epithelial-mesenchymal transition and promotes cancer metastasis by
regulating ZEB1 expression. Cancer Res. 74:520–531. 2014.
View Article : Google Scholar :
|
|
49
|
Zhang G, He P, Gaedcke J, Ghadimi BM, Ried
T, Yfantis HG, Lee DH, Hanna N, Alexander HR and Hussain SP: FOXL1,
a novel candidate tumor suppressor, inhibits tumor aggressiveness
and predicts outcome in human pancreatic cancer. Cancer Res.
73:5416–5425. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ohashi S, Natsuizaka M, Naganuma S, Kagawa
S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, et
al: A NOTCH3-mediated squamous cell differentiation program limits
expansion of EMT-competent cells that express the ZEB transcription
factors. Cancer Res. 71:6836–6847. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eger A, Aigner K, Sonderegger S, Dampier
B, Oehler S, Schreiber M, Berx G, Cano A, Beug H and Foisner R:
DeltaEF1 is a transcriptional repressor of E-cadherin and regulates
epithelial plasticity in breast cancer cells. Oncogene.
24:2375–2385. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Xu X, Sun PL, Li JZ, Jheon S, Lee CT and
Chung JH: Aberrant Wnt1/β-catenin expression is an independent poor
prognostic marker of non-small cell lung cancer after surgery. J
Thorac Oncol. 6:716–724. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
He B, You L, Uematsu K, Xu Z, Lee AY,
Matsangou M, McCormick F and Jablons DM: A monoclonal antibody
against Wnt-1 induces apoptosis in human cancer cells. Neoplasia.
6:7–14. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Brabletz T, Jung A, Reu S, Porzner M,
Hlubek F, Kunz-Schughart LA, Knuechel R and Kirchner T: Variable
beta-catenin expression in colorectal cancers indicates tumor
progression driven by the tumor environment. Proc Natl Acad Sci
USA. 98:10356–10361. 2001. View Article : Google Scholar : PubMed/NCBI
|
